Thomas McFadden
Greenville, SCNPI 1588618334
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 68.0% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2021 at $956 and has fallen 60.7% since, to $376 in 2025.
Across 143 payments — averaging $31.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Sientra, Inc.$419
- Motiva USA, LLC$208
- TELA Bio, Inc.$196
- Merz North America, Inc.$195
- Mentor Worldwide LLC$131
- plus $288 from 7 others
Across 2 payments — averaging $515.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Food & beverage$4,500100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $3,062 |
| Sientra, Inc. | 9 | $419 |
| Motiva USA, LLC | 4 | $208 |
| TELA Bio, Inc. | 5 | $196 |
| Merz North America, Inc. | 2 | $195 |
| Mentor Worldwide LLC | 3 | $131 |
| Acelrx Pharmaceuticals, Inc. | 5 | $86 |
| Galderma Laboratories, L.p. | 4 | $62 |
| Osiris Therapeutics Inc. | 1 | $58 |
| Baxter Healthcare | 1 | $27 |
| Davol Inc. | 1 | $25 |
| Smith+Nephew | 1 | $15 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nitro-BidNitroglycerin | 11 | $381 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 75 | $243 |
| Scopolamine | 14 | $186 |
| Celecoxib | 33 | $140 |
| Gabapentin | 51 | $101 |
| Ondansetron OdtOndansetron | 29 | $90 |
| Triamcinolone Acetonide | 16 | $70 |
| Ibuprofen | 46 | $68 |
| ValacyclovirValacyclovir Hcl | 16 | $66 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $38 |
| Amoxicillin | 29 | $23 |
| Diazepam | 21 | $16 |
| Clonidine Hcl | 24 | $9 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.